

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 9

Complete if Known

Application Number	10/570,734
Filing Date	October 18, 2006
First Named Inventor	Fernando Albericio Palomera
Art Unit	1654
Examiner Name	Ronald T. Niebauer
Attorney Docket Number	13566.105010

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		4,943,533	07-24-1990	John Mendelsohn	
		5,457,105	10-10-1995	Andrew J. Barker	
		5,558,864	09-24-1996	Mary M. Bendig	
		5,770,599	06-23-1998	Keith H. Gibson	
		5,747,498	05-05-1998	Rodney C. Schnur	
		5,891,996	04-06-1999	Cristina M. Mateo De Acosta Del Rio	
		6,200,598	03-13-2001	David Needham	
		6,235,883	05-22-2001	Aya Jakobovits	
		RE 39496	02-27-2007	Paul J. Scheuer	
		6,344,455	02-05-2002	Alexander James Bridges	
		6,391,874	05-21-2002	George Stuart Cockerill	
		6,713,485	03-30-2004	Malcolm Clive Carter	
		6,727,256	04-27-2004	Malcolm Clive Carter	
		6,900,221	05-31-2005	Timothy Norris	
		7,323,444	01-29-2008	Miguel Angel Izquierdo Delso	
		7,482,429	01-27-2009	Fernando Albericio	
		7,507,708	03-24-2009	Glynn Thomas Faircloth	
		7,683,028	03-23-2010	Glynn Thomas Faircloth	
		2004/0071768	04-15-2004	Andreas H. Sarris	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				<i>Application Number</i>	10/570,734
				<i>Filing Date</i>	October 18, 2006
				<i>First Named Inventor</i>	Fernando Albericio Palomera
				<i>Art Unit</i>	1654
				<i>Examiner Name</i>	Ronald T. Niebauer
Sheet	2	of	9	<i>Attorney Docket Number</i>	13566.105010

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Aillon, K. L. et al., "Effects of Nanomaterial physicochemical properties on in vivo toxicity," Adv. Drug. Deliv. Rev. 2009, 61, 457-466	
		Alivisatos, P., "The use of nanocrystals in biological detection," Nature Biotech. 2004, 22, 47-52	
		Arora, A et al., "Role of Tyrosine Kinase Inhibitors in Cancer Therapy," Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 971-979	
		Baba, T. et al., Microarray analysis identifies NSC668814 as a potentially active chemotherapeutic agent for platinum-resistant ovarian cancers with TP53 mutations [abstract] In: Proceedings of the 39 th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncologists; 2008 March 9-12; Tampa, Florida. Chicago (IL); SGO; 2008. Abstract no 160; and the corresponding poster presented in said congress	
		Bensebaa, F. et al., "XPS study of metal-sulfur bonds in metal-alkanethiolate materials," Surf. Sci. 1998, 405, L472-L476	
		Boisselier, E. et al., "Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity," Chem. Soc. Rev. 2009, 38, 1759-1782	
		Bruce, J. Y. et al., Phase I study of PM02734: Association of dose-limiting hepatotoxicity with plasma concentrations [abstract] IN: Proceedings of the 44 th Annual Meeting of the American Society of Clinical Oncology; 2008 May 30 – Jun 3; Chicago, IL. Alexandria (VA): ASCO; 2008. Abstract no 2513; and the corresponding poster presented in said congress	
		Chen et al., "Methotrexate Conjugated to Gold Nanoparticles Inhibits Tumor Growth in a Syngeneic Lung Tumor Model," Mol. Pharmaceutics, 2007, 4, 713-722	
		Chithrani et al., "Elucidating the Mechanism of Cellular Uptake and Removal of Protein-Coated Gold Nanoparticles of Different Sizes and Shapes," Nano Lett. 2007, 7, 1542-1550	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				<i>Application Number</i>	10/570,734
				<i>Filing Date</i>	October 18, 2006
				<i>First Named Inventor</i>	Fernando Albericio Palomera
				<i>Art Unit</i>	1654
				<i>Examiner Name</i>	Ronald T. Niebauer
Sheet	3	of	9	<i>Attorney Docket Number</i>	13566.105010

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Coronado, C. et al., "Elisidepsin," Drugs of the Future, 2010, 35, 287-296	
		Evans, T. R. et al., Phase I dose-escalating, study of PM02734 in a 24-hour infusion schedule every 21 days in advance solid tumors [abstract] In: Proceedings of the 45 th Annual Meeting of the American Society of Clinical Oncology; 2009 May 29 – Jun 2; Orlando, FL. Alexandria (VA): ASCO; 2009. Abstract nr 2511; and the corresponding poster presented in said congress	
		Faircloth, G. T. et al., Selective Antitumor Activity of Kahalalide F, A Marine-Derived Cyclic Depsipeptide [abstract]. In: Proceedings of the 94 th Annual Meeting of the American Association for Cancer Research; Vol. 42, March 2001. Abstract no 1140	
		Frens, G. et al., "Controlleed Nucleation for the Regulation of the Particle Size in Monodisperse Gold Suspensions," Nature Phys. Sci., 1973, 241, 20-22	
		Galmarini, C. M., New marine anticancer agents in development [abstract] In: 6 th European Spring Oncology Conference; 2010 Jun 22-25; Marbella, Málaga. España: ESOC; 2010. Vol. 12, p 26; and the corresponding presentation presented in said congress	
		García-Rocha, M. et al., "The antitumoral compound Kahalalide F acts on cell lysosomes," Cancer Lett., 1996, 99, 43-50	
		Geoerger, B. et al., Evaluation of the marine compound PM02734 against a pediatric tumor cell line panel by ITCC preclinical drug evaluation program [abstract] In: 20 th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; 2008 Oct 22-24; Geneva, Switzerland. Philadelphia (PA): AACR; 2008. Abstract no 181; and the corresponding poster presented in said congress	
		Gibson et al., "Paclitaxel-Functionalized Gold Nanoparticles," J. Am. Chem. Soc., 2007, 129, 11653-11661	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4 of 9

Complete if Known

Application Number	10/570,734
Filing Date	October 18, 2006
First Named Inventor	Fernando Albericio Palomera
Art Unit	1654
Examiner Name	Ronald T. Niebauer
Attorney Docket Number	13566.105010

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Giljohann, D. A. et al., "Gold Nanoparticles for biology and medicine," Angew. Chem. Int. Ed., 2010, 49, 3280-3294	
		Hernandez-Losa, J. et al., Downregulation of ErbB3 expression and inhibition of Akt pathway by PM02734; <i>invitro</i> synergism of the combination with cisplatin in breast, colon and lung cancer cell lines [abstract] In: Proceedings of the 99 th Annual Meeting of the American Association for Cancer Research; 2008 Apr 12-16; San Diego, CA. Philadelphia (PA): AACR; 2008. Abstract no 1473; and the corresponding poster presented in said congress	
		Herrero, A. B. et al., "Levels of SCS7/FA2H-Mediated Fatty Acid 2-Hydroxylation Determine the Sensitivity of Cell to Antitumor PM02734," Cancer Res., 2008, 68, 9779-9787	
		Hosta, L. et al., "Conjugation of Kahalalide F with Gold Nanoparticles to Enhance in Vitro Antitumoral Activity," Bioconjug. Chem., 2008, 20, 138-146	
		Hynes, N. E. et al., "ErbB Receptors and Cancer: The Complexity of Targeted Inhibitors," Nature Rev., 2005, 5, 341-354	
		Jain et al., "Calculated Absorption and Scattering Properties of Gold Nanoparticles of Different Size, Shape and Composition: Applications in Biological Imaging and Biomedicine," J. Phys. Chem. B 2006, 110, 7238-7248	
		Janmaat, M. L. et al., Kahalalide F (KF) induces cell death in Her2/neu overexpressing breast cancer cells that is independent of caspase, cathepsin B, and cathepsin D activity [abstract]. In: Proceedings of the 2 nd International Symposium on Signal Transduction Modulators in Cancer Therapy; 2003 October 23-25; Amsterdam, 2003:60. Abstract no B02	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/570,734
				Filing Date	October 18, 2006
				First Named Inventor	Fernando Albericio Palomera
				Art Unit	1654
				Examiner Name	Ronald T. Niebauer
Sheet	5	of	9	Attorney Docket Number	13566.105010

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Janmaat, M. L. et al., "Khalalide F induces Necrosis-Like Cell Death that Involves Depletion of ErbB3 and Inhibition of Akt Signaling," Mol. Pharm., 2005, 68, 502-510	
		Kim et al., "Designed Fabrication of Multifunctional Magnetic Gold Nanoshells and Their Application to Magnetic Resonance Imaging Photothermal Therapy," Angew. Chem. Int. Ed., 2006, 45, 7754-7758	
		Kogan, M. J. et al., "Nanoparticle-Mediated Local and Remote Manipulation of Protein Aggregation," Nano Lett., 2006, 6, 110-115	
		Ling, Y.- H. et al., "Erlotinib, an Effective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Induces p27 ^{KIP1} Up-Regulation and Nuclear Translocation in Association with Cell Growth Inhibition and G1/S Phase Arrest in Human Non-Small-Cell Lung Cancer Cell Lines," Molecular Pharmacology, 2007, 72(2), 248-258	
		Ling, Y.- H. et al., "In Vitro Cytotoxicity, Cellular Pharmacology, and DNA Lesions Induced by Annamycin, an Anthracycline Derivative with High Affinity for Lipid Membranes," Cancer Res., 1993, 53, 1583-1589	
		Ling, Y.- H. et al., Irvallec (PM02734) induces caspase-independent autophagic cell death in human non-small cell lung cancer cell lines through the inhibition of akt/mtor signaling pathways and activation of death associated protein kinase [abstract] In: Proceedings of the 100 th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 2656; and the corresponding poster presented in said congress	
		Ling, Y.- H. et al., "Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models," Eur. J. Cancer, 2009, 45, 1855-1864	
		Mayer, A. M. S. et al., "The Odyssey of marine pharmaceuticals: a current pipeline perspective," Cell, 2010, 31, 255-265	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/570,734
				Filing Date	October 18, 2006
				First Named Inventor	Fernando Albericio Palomera
				Art Unit	1654
				Examiner Name	Ronald T. Niebauer
				Attorney Docket Number	13566.105010
Sheet	6	of	9		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Medina, L. et al., Investigation of the Effects of Kahalalide F (PM92102) Against Human Tumor Specimens taken directly from patients [abstract]. In: Proceedings of the 94 th Annual Meeting of the American Association for Cancer Research; Vol. 42, March 2001, Abstract no 1139	
		Molina-Guijarro, J. M. et al., Modulation of the early cytotoxic effects of Irvaltec® by zinc and DIDS in lung tumor cells [abstract] In: Proceedings of the 101 th Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; 2010. Abstract no 4454; and the corresponding poster presented in said congress	
		Molina-Guijarro. et al., PM02734, a new marine-derived antitumoral compound, has rapid effects on membrane integrity and permeability in tumor cells [abstract] In: Proceedings of the 100 th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia PA: AACR, 2009. Abstract no 888; and the corresponding poster presented in said congress	
		Osaki, et al., "A Quantum Dot Conjugated Sugar Ball and Its Cellular Uptake. On the size Effects of Endocytosis in the Subviral Region" J. Am. Chem. Soc., 2004, 126, 6520-6521	
		Paciotti, G. F. et al., "Colloidal Gold: A Novel Nanoparticle Vector for Tumor Directed Drug Delivery," Drug Delivery 2004, 11, 169-183	
		Paciotti, G. F. et al., "Colloidal Gold Nanoparticles: A Novel Nanoparticle Platform for Developing Multifunctional Tumor-Targeted Drug Delivery Vectors" Drug Dev.Re., 2006, 67, 47-54	
		Pérez-Soler, R. et al., PM02734 (Irvaltec), a novel synthetic cyclic peptide compound, induces caspase-independent autophagic cell death in human non-small cell lung cancer cell lines through the inhibition of Akt/mTOR signaling pathways and activation of DARK. [abstract] In: AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics; 2009 Nov 15-19; Boston, MA. Philadelphia (PA): AACR; 2009. Abstract no C2	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/570,734
				Filing Date	October 18, 2006
				First Named Inventor	Fernando Albericio Palomera
				Art Unit	1654
				Examiner Name	Ronald T. Niebauer
Sheet	7	of	9	Attorney Docket Number	13566.105010

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Pérez-Soler, R. et al., Synergism between PM02734 and erlotinib in human non-small cell lung cancer cell lines [abstract] In: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2007 Oct 22-26; San Francisco, CA. Philadelphia (PA): AACR; 2007. Abstract no C179; and the corresponding poster presented in said congress	
		Provencio, M. <i>et al.</i> "Cancer Treatments: Can We Find Treasures at the Bottom of the Sea?" Clin. Lung Cancer, 2009, 10, 295-300	
		Sagara, T. et al., "Electroreflectance Study of Gold nanoparticles Immobilized on an Aminoalkanethiol Monolayer Coated on a Polycrystalline Gold Electrode Surface" <i>J. Phys. Chem. B</i> 2002, 106, 1205-1212	
		Santabarbara, P. Present and Future of Marine Anticancer Compounds [abstract] In: 5 th European Spring Oncology Conference; 2008 Jun 25-27; Marbella, Málaga. España: ESOC; 2008. Abstract no 20	
		Sasak, H. et al., PM02734 Cytotoxicity <i>In Vitro</i> and Pharmacokinetics [Poster] In: Proceedings of the 97 th Annual Meeting of the American association for Cancer Research; 2006 April 1-5; Whashington, DC. Philadelphia (PA): AACR; 2006. Abstract no 1911	
		Serova, M. et al., Antiproliferative Effects of PM02734, a novel cyclic peptide compared with currently used Erb-B Inhibitors, in a panel of human cancer cells lines characterized for Erb-B express. In: 20 th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; 2008 Oct 22-24; Geneva, Switzerland. Philadelphia (PA): AACR; 2008. Abstract no 317; and the corresponding poster presented in said congress	
		Serova, M. et al., Characterization of genetic factors associated with sensitivity to Irvalec, a novel marine-derived compound. In: Proceedings of the 100 th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR, 2009. Abstract no 857; and the corresponding poster presented in said congress	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				<i>Application Number</i>	10/570,734
				<i>Filing Date</i>	October 18, 2006
				<i>First Named Inventor</i>	Fernando Albericio Palomera
				<i>Art Unit</i>	1654
				<i>Examiner Name</i>	Ronald T. Niebauer
				<i>Attorney Docket Number</i>	13566.105010
Sheet	8	of	9		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Serova, M. et al., Epthelial-to-mesenchymal transition (EMT) in resistance to the antiproliferative effects of elisidepsin (Irvalec TM), a novel marine-derived depsipeptide, in colon cancer cells [abstract] In: AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics; 2009 Nov 15-19; Boston, MA. Philadelphia (PA): AACR; 2009. Abstract no B151; and the corresponding poster presented in said congress	
		Serova, M. et al., Irvalec, a novel marine cyclic peptide, enhances the antiproliferative affects of other anticancer drugs in human cancer cell lines [abstract] In: Proceedings of the 100 th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract no 4569; and the corresponding poster presented in said congress	
		Serova, M. et al., Molecular mechanism associated with sensitivity/resistance to PM02734 (Irvalec®), a novel marine-derived cyclic depsipeptide [abstract] In: Proceedings of the 101th Annual Meeting of the American Association for Cancer Research; 2010Apr 17-21; Washington, DC. Philadelphia (PA): AACR, 2010. Abstract no 1542; and the corresponding poster presented in said congress	
		Sewell et al., "The Mechanism of action of Kahalalide F: Variable cell permeability in human hepatoma cell lines" European J. Cancer, 2005, 41, 1637-1644	
		Shilabin et al., "Lysosome and Her3 (ErbB3) Selective Anticancer Agent Kahalalide F: Semisynthetic Modifications and Antifungal Nead-Exploration Studies" J. Med. Chem. 2007, 50, 4340-4350	
		Steegh, N. et al. "Small Molecule Tyrosine Inhibitors in the Treatment of Solid Tumors: An Update of Recent Developments" Annals of Surgical Oncology 2006, 14, 942-953	
		Suárez, Y. et al., "Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells" Mol. Cancer Ther. 2003, 2, 863-872	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				<i>Application Number</i>	10/570,734
				<i>Filing Date</i>	October 18, 2006
				<i>First Named Inventor</i>	Fernando Albericio Palomera
				<i>Art Unit</i>	1654
				<i>Examiner Name</i>	Ronald T. Niebauer
Sheet	9	of	9	<i>Attorney Docket Number</i>	13566.105010

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Sun, L. et al., "Functional Gold Nanoparticle-Peptide Complexes as Cell-Targeting Agents" <i>Langmuir</i> 2008, 24, 10293-10297	
		Tkachenko et al., "Multifunctional Gold Nanoparticles-Peptide Complexes for Nuclear Targeting," <i>J. Am. Chem. Soc.</i> 2003, 125, 4700-4701	
		Tkachenko et al., "Cellular Trajectories of Peptide-Modified Gols Particle Complexes: Comparison of Nuclear Localization Signals and Peptide Transduction Domains," <i>Bioconjugate Chem.</i> 2004, 15, 482-490	
		Varadi, T. et al., C-erbB3 protein modifications are secondary to severe cell membrane alterations induced by Irvalec treatment in CHO cells [abstract] In: Proceedings of the 101th Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-20; Washington, DC. Philadelphia (PA): AACR; 2010. Abstract nr 4464; and the corresponding poster presented in said congress	
		Visaria, R. K. et al., "Enhancement of tumor termal therapy using gold nanoparticle assisted tumor necrosis factor-alfa delivery" <i>Mol. Cancer Ther.</i> 2006, 5, 1014-1020	
		Wosikowski et al., "Identification of Epidermal Growth Factor Receptor and c-erbB2 Pathway Inhibitors by Correlation With Gene Expression Patterns" <i>J. Natl. Cancer Inst.</i> 1997, 89, 1505-1515	
		Xu et al., "Inorganic nanoparticles as carriers for efficient cellular delivery," <i>Chem. Eng. Sci.</i> 2006, 61, 1027-1040	
		Yin, J. et al., "Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM02734, a novel antineoplastic agent, in dog plasma" <i>Rapid Commun. Mass. Spectrom.</i> 2006, 20, 2735-2740	
		Zou, Y. et al. Antitumor activity of Irvalec (PM02734) against lung cancer xenografts [abstract] In: Proceedings of the 100 th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract no 5466; and the corresponding poster presented in said congress	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.